- $31.89bn
- $33.90bn
- $9.89bn
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Street View: Spotlight turns to Biogen's pipeline
U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup
Brief: Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China
U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina
Biogen forecasts upbeat annual profit, eyes 2028 launch of key drugs (updated)
U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison
U.S. STOCKS ON THE MOVE-Biogen, Bloom Energy, Ubiquiti
Biogen Q4 results beat; forecasts 2026 adj EPS $15.25-$16.25
Biogen rises after beating annual profit estimates
Brief: Biogen Q4 Adjusted EPS USD 1.99 Vs. IBES Estimate USD 1.59
Revenue Of Leqembi (Preliminary Basis)
Biogen forecasts annual profit above estimates as Leqembi sales pick up
Brief: Biogen Sees 2026 Adj EPS $15.25 - $16.25 Versus IBES Estimate $14.92
What to Watch in the Day Ahead - Friday, February 6
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Brief: Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review